Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet, Journal Year: 2016, Volume and Issue: 389(10066), P. 255 - 265

Published: Dec. 13, 2016

Language: Английский

---

The future of immune checkpoint therapy

Science, Journal Year: 2015, Volume and Issue: 348(6230), P. 56 - 61

Published: April 2, 2015

Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led important clinical advances and provided a new weapon against cancer. This therapy elicited durable responses and, fraction of patients, long-term remissions where patients exhibit no signs cancer for many years. The way forward this class novel agents lies our ability understand human the tumor microenvironment. will provide valuable information regarding dynamic nature response regulation additional that need be targeted through combination therapies survival benefit greater numbers patients.

Language: Английский

---

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Nature, Journal Year: 2018, Volume and Issue: 554(7693), P. 544 - 548

Published: Feb. 1, 2018

Language: Английский

---

The biology and management of non-small cell lung cancer

Nature, Journal Year: 2018, Volume and Issue: 553(7689), P. 446 - 454

Published: Jan. 1, 2018

Language: Английский

---

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Cancer Cell, Journal Year: 2015, Volume and Issue: 27(4), P. 450 - 461

Published: April 1, 2015

Language: Английский

---

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 379(22), P. 2108 - 2121

Published: Oct. 20, 2018

Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)–paclitaxel may enhance the anticancer activity of atezolizumab.

Language: Английский

---

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

The Lancet, Journal Year: 2016, Volume and Issue: 387(10031), P. 1909 - 1920

Published: March 5, 2016

Language: Английский

---

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

Cell, Journal Year: 2015, Volume and Issue: 160(1-2), P. 48 - 61

Published: Jan. 1, 2015

How the genomic landscape of a tumor shapes and is shaped by anti-tumor immunity has not been systematically explored. Using large-scale data sets solid tissue biopsies, we quantified cytolytic activity local immune infiltrate identified associated properties across 18 types. The number predicted MHC Class I-associated neoantigens was correlated with lower than expected in colorectal other tumors, suggesting immune-mediated elimination. We recurrently mutated genes that showed positive association activity, including beta-2-microglobulin (B2M), HLA-A, -B -C Caspase 8 (CASP8), highlighting loss antigen presentation blockade extrinsic apoptosis as key strategies resistance to activity. Genetic amplifications were also high immunosuppressive factors such PDL1/2 ALOX12B/15B. Our genetic findings thus provide evidence for immunoediting tumors uncover mechanisms tumor-intrinsic

Language: Английский

---

Tumour-associated macrophages as treatment targets in oncology

Nature Reviews Clinical Oncology, Journal Year: 2017, Volume and Issue: 14(7), P. 399 - 416

Published: Jan. 24, 2017

Language: Английский

---

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 378(24), P. 2288 - 2301

Published: June 4, 2018

The cancer-cell-killing property of atezolizumab may be enhanced by the blockade vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated plus bevacizumab chemotherapy in patients metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.We randomly assigned to receive carboplatin paclitaxel (ACP), (BCP), or BCP (ABCP) every weeks for four six cycles, followed maintenance therapy atezolizumab, bevacizumab, both. two primary end points were investigator-assessed progression-free survival both among intention-to-treat population a wild-type genotype (WT population; EGFR ALK genetic alterations excluded) and WT high expression an effector T-cell (Teff) gene signature tumor (Teff-high population) overall population. ABCP group was compared before ACP group.In population, 356 group, 336 group. median longer than (8.3 months vs. 6.8 months; hazard ratio disease progression death, 0.62; 95% confidence interval [CI], 0.52 0.74; P<0.001); corresponding values Teff-high 11.3 (hazard ratio, 0.51 [95% CI, 0.38 0.68]; P<0.001). Progression-free also entire (including those alterations) low negative programmed death ligand 1 (PD-L1) expression, Teff gene-signature liver metastases. Median (19.2 14.7 0.78; 0.64 0.96; P=0.02). safety profile consistent reported risks individual medicines.The addition significantly improved NSCLC, regardless PD-L1 alteration status. (Funded F. Hoffmann-La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143 .).

Language: Английский

---